Abstract

Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.

Original languageEnglish
Pages (from-to)100-115
Number of pages16
JournalPublic Health Genomics
Volume20
Issue number2
DOIs
Publication statusPublished - 01-09-2017

Fingerprint

Precision Medicine
Epigenomics
Uterine Cervical Neoplasms
Histone Code
Untranslated RNA
DNA Methylation
Cytosine
Drug Discovery
Chromatin
Carcinogenesis
Genome
RNA
Gene Expression
Enzymes
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Genetics(clinical)

Cite this

@article{f74afa84a70247eebb37bf64ccdb51c9,
title = "Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer",
abstract = "Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.",
author = "Kabekkodu, {Shama Prasada} and Sanjiban Chakrabarty and Supriti Ghosh and Angela Brand and Kapaettu Satyamoorthy",
year = "2017",
month = "9",
day = "1",
doi = "10.1159/000475804",
language = "English",
volume = "20",
pages = "100--115",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "2",

}

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer. / Kabekkodu, Shama Prasada; Chakrabarty, Sanjiban; Ghosh, Supriti; Brand, Angela; Satyamoorthy, Kapaettu.

In: Public Health Genomics, Vol. 20, No. 2, 01.09.2017, p. 100-115.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

AU - Kabekkodu, Shama Prasada

AU - Chakrabarty, Sanjiban

AU - Ghosh, Supriti

AU - Brand, Angela

AU - Satyamoorthy, Kapaettu

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.

AB - Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=85019857482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019857482&partnerID=8YFLogxK

U2 - 10.1159/000475804

DO - 10.1159/000475804

M3 - Review article

AN - SCOPUS:85019857482

VL - 20

SP - 100

EP - 115

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 2

ER -